Two China biotechs drop US IPO plans for $800 million Hong Kong floats

HONG KONG: Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in on new rules to woo early-stage drug developers, sources said. Fidelity Investments-backed Innovent …
( read original story …)